The aim of our study was to evaluate and further validate the prognostic biomarker significance of serum VEGF levels in advanced melanoma patients treated with anti-CTLA4 (ipilimumab), anti-PD1 agents (pembrolizumab/ or nivolumab) or the combination of ipilimumab and nivolumab. This evidence concerns the gene VEGFA and melanoma.